A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate complete response plus (+) very good partial
response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination
with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated
subjects, and in relapsed subjects with multiple myeloma, as defined by the International
Myeloma Working Group (IMWG) criteria.